Teruhiro Utsugi

Learn More
Many pharmaceutical companies worldwide specialize in oncology drug development and marketing. Among them, we have continued to take up the challenge of understanding the metabolism of pyrimidines as essential components of deoxyribonucleic acid for many years, and have provided unique products such as UFT(®) and TS-1 for cancer patients. Using our(More)
Heat shock protein 90 (HSP90) is a highly conserved molecular chaperone that interacts with various client proteins in eukaryotic cells 1 : Akt (PI3K/Akt pathway), IL-6R (JAK/ STAT pathway), Bcr-Abl (RAS/ERK pathway), CDK4, 6, 9 (cell cycling), and IκB kinases (NF-κB pathway). 2 The expression of HSP90 is upregulated (2-to 10-fold) in tumor cells compared(More)
Heat shock protein (HSP)90 inhibitors have shown significant anti-tumor activities in preclinical settings in both solid and hematological tumors. We previously reported that the novel, orally available HSP90α/β inhibitor TAS-116 shows significant anti-MM activities. In this study, we further examined the combination effect of TAS-116 with a RAS-RAF-MEK-ERK(More)
  • 1